Clin. exp. Immunol. (1990) 80, 268-273

In vivo treatment with anti B-220 monoclonal antibody affects T and B cell differentiation V. ASENSI, K. HIMENO,

I.

KAWAMURA, M. SAKUMOTO & K. NOMOTO Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan (Acceptedfor publication 14 November 1989)

SUMMARY The B220 cell marker is expressed on B cells and on T cell precursors. In order to determine the involvement of the B220 antigen on murine lymphoid differentiation, we treated 5-10-week-old mice periodically with a specific anti-B220 antibody, RA3-6B2, a non-cytolytic IgG2b. After the third injection, a significant reduction (P < 0 02) in the number of thymocytes and less dramatically in the number of splenocytes was observed. This reduction was predominantly due to a decrease of cells carrying the following markers: Thy-1.2+, Lyt-l+, Lyt-2.3+, L3T4+, and asGMl+. Mitogenic response to concanavalin A, phytohaemagglutinin and lipopolysaccharide, mixed lymphocyte reaction, cytotoxic T cell activity, and plaque-forming cell generation were significantly decreased after the treatment (P

In vivo treatment with anti B-220 monoclonal antibody affects T and B cell differentiation.

The B220 cell marker is expressed on B cells and on T cell precursors. In order to determine the involvement of the B220 antigen on murine lymphoid di...
958KB Sizes 0 Downloads 0 Views